Drug intelligence / Profile preview

APC-5000

Development stage: Preclinical
Lead developer: Adamis Pharmaceuticals
Administration: Inhalation

Overview

APC-5000 is a respiratory drug candidate developed by Adamis Pharmaceuticals for the treatment of asthma and chronic obstructive pulmonary disease (COPD). The drug is designed to be delivered using a dry powder inhaler (DPI) technology, known as Taper DPI, which Adamis Pharmaceuticals acquired or licensed from 3M. The development of APC-5000 is part of Adamis' pipeline products aimed at respiratory and allergy conditions.

Beyond the preview

Go deeper on APC-5000.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on APC-5000.

Explore the full profile